Drug Trial Radar · NCT06630234
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
155
Planned (sponsor's estimate)
Start
Dec 10, 2024
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 3 parts: Part 1 (Dose Escalation), Part 2 (Dose Expansion), and Part 3 (Food Effect \[FE\] and Drug-Drug Interaction \[DDI\]). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Conditions
- Gastrointestinal Stromal Tumor (GIST)
Interventions
DCC-3009Drug
Administered orally
RabeprazoleDrug
Administered orally (Part 3 only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
- Number of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
- Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
- Objective Response Rate (ORR) (Part 2 Expansion)Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
- Pharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
- PK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
- PK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
- PK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth
Scottsdate, Arizona · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Vanderbilt University-Ingram Cancer Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.